Literature DB >> 34738148

Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1.

Zhiqing Mo1, Hao Ding1, Xiaojiao Zhou1, Zisan Zeng2, Liling Long3.   

Abstract

PURPOSE: The RAF1 expression affects prognosis in patients with hepatocellular carcinoma (HCC) treated with sorafenib. We examined the expression of sorafenib-targeted gene RAF1 to ascertain its relationship with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (MRI) characteristics. We also explored the predictive potential of RAF1 expression markers in the treatment of HCC. PATIENTS AND METHODS: Sixty-five patients with HCC who underwent preoperative enhanced MRI scanning were included in this study. We analyzed the qualitative and quantitative characteristics of enhanced MRI findings in patients with HCC. Immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR) analyses were used to detect the protein and mRNA expression levels of RAF1 in HCC. Correlation and logistic regression analyses were used to evaluate the relationship between these image features and the RAF1 gene expression levels in HCC.
RESULTS: The IHC analysis indicated a significant difference in tumor thrombus group (P = 0.037), RT-PCR results revealed a significant between-group difference for both tumor margins (P = 0.033) and capsule (P = 0.04). Binary logistic regression analysis results suggest that independent MRI predictors were regular tumor margins [P = 0.035, odds ratio (OR) = 3.145, 95% confidence interval (CI) 1.087-9.103] and thrombus (P = 0.046, OR = 4.421, 95% CI 1.024-19.08) with high RAF1expression; the tumor capsule was not an independent predictor.
CONCLUSION: We found a correlation between MRI features and the RAF1 gene expression, Regular tumor margin and the presence of tumor thrombus are indicators of high RAF1 expression in HCC. Enhanced MRI may be useful for identifying patients with HCC eligible for targeted treatment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hepatocellular carcinoma; Magnetic resonance imaging; RAF1; Tumor thrombus

Mesh:

Substances:

Year:  2021        PMID: 34738148     DOI: 10.1007/s00261-021-03325-z

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  2 in total

1.  MRI features of hepatocellular carcinoma expressing progenitor cell markers.

Authors:  Hyeon Tae Jeong; Myeong-Jin Kim; Yeo-Eun Kim; Young Nyun Park; Gi Hong Choi; Jin Sub Choi
Journal:  Liver Int       Date:  2011-09-13       Impact factor: 5.828

2.  Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma.

Authors:  Guo Gang; Yu Hongkai; Zhang Xu
Journal:  J Cancer Res Ther       Date:  2015 Oct-Dec       Impact factor: 1.805

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.